You have 9 free searches left this month | for more free features.

Navitoclax

Showing 1 - 25 of 40

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level

Not yet recruiting
  • Relapsed Adult AML
  • Refractory AML
  • Navitoclax Dose Level -1
  • +10 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Myeloid Malignancy, MDS, Myelofibrosis Trial in Boston (Navitoclax, Venetoclax, Decitabine)

Recruiting
  • Myeloid Malignancy
  • +4 more
  • Navitoclax
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jul 21, 2022

High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer Trial (Olaparib tablet, Navitoclax)

Recruiting
  • High Grade Serous Carcinoma
  • +2 more
  • Olaparib tablet
  • Navitoclax
  • Toronto, Ontario, Canada
  • +2 more
Nov 28, 2022

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 22, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Memphis (drug, biological, radiation)

Not yet recruiting
  • Refractory Acute Lymphoblastic Leukemia
  • Relapsed Acute Lymphoblastic Leukemia
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 23, 2022

Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma Trial in Dallas (Venetoclax, Navitoclax)

Available
  • Relapsed Childhood ALL
  • Relapsed Childhood Lymphoblastic Lymphoma
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Feb 28, 2022

Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Boston

Active, not recruiting
  • Metastatic Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +6 more
  • Boston, Massachusetts
  • +1 more
Nov 8, 2022

Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia

Recruiting
  • Myelodysplastic Syndrome
  • +2 more
  • Navitoclax
  • +6 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023

Myelofibrosis (MF) Trial in Korea, Republic of, South Africa, United States (Mivebresib, Navitoclax, Ruxolitinib)

Active, not recruiting
  • Myelofibrosis (MF)
  • Stony Brook, New York
  • +6 more
Mar 23, 2022

Metastatic Malignant Solid Tumor, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Tumor Trial in United States

Terminated
  • Metastatic Malignant Solid Neoplasm
  • +8 more
  • Los Angeles, California
  • +13 more
Oct 7, 2022

Acute Lymphoblastic Leukemia Trial in Israel (Navitoclax, Venetoclax)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • Be'er Sheva, Israel
  • +5 more
Sep 14, 2021

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung

Active, not recruiting
  • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
  • +5 more
  • Sacramento, California
  • +17 more
Aug 2, 2022

Myeloproliferative Tumor Trial in Worldwide (Navitoclax, Ruxolitinib, Celecoxib)

Recruiting
  • Myeloproliferative Neoplasm
  • Navitoclax
  • +2 more
  • Duarte, California
  • +41 more
Feb 1, 2023

Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Trial in Australia, United States (Navitoclax, Chemotherapy,

Completed
  • Acute Lymphoblastic Leukemia (ALL)
  • Lymphoblastic Lymphoma
  • Navitoclax
  • +2 more
  • Duarte, California
  • +14 more
Oct 7, 2021

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in

Active, not recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +4 more
  • Phoenix, Arizona
  • +48 more
Jan 3, 2023

Chronic Lymphocytic Leukemia Trial in Worldwide (ABT-263)

Completed
  • Chronic Lymphocytic Leukemia
  • La Jolla, California
  • +9 more
Jul 8, 2022

Myelofibrosis (MF) Trial in Worldwide (Navitoclax, Ruxolitinib, Best Available Therapy (BAT))

Recruiting
  • Myelofibrosis (MF)
  • Navitoclax
  • +2 more
  • Chandler, Arizona
  • +207 more
Jul 26, 2022

Myelofibrosis (MF) Trial in Worldwide (Ruxolitinib, Navitoclax)

Active, not recruiting
  • Myelofibrosis (MF)
  • Birmingham, Alabama
  • +149 more
Nov 5, 2021

Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma Trial in Canada, United States (ABT-263)

Completed
  • Chronic Lymphoid Leukemia
  • +5 more
  • Los Angeles, California
  • +11 more
Jul 28, 2021

Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)

Active, not recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022

Lymphoma, Including Chronic Lymphocytic Leukemia, Solid Tumors Trial (navitoclax, Rifampin)

Completed
  • Lymphoma, Including Chronic Lymphocytic Leukemia
  • Solid Tumors
  • (no location specified)
Nov 17, 2017

Solid Tumors Trial (ABT-263, gemcitabine)

Completed
  • Solid Tumors
  • (no location specified)
Nov 17, 2017

Solid Tumors Trial (ABT-263, paclitaxel)

Completed
  • Solid Tumors
  • (no location specified)
Nov 17, 2017